Guardant Almanac

Guardant Almanac

Title: A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)

Associated condition: Colorectal Cancer/ Colonoscopy

Status: Currently enrolling

Brief summary: The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer.

Primary objectives: 

  1. Sensitivity of colorectal cancer detection
  2. Specificity of advanced neoplasia detection

Estimated length of study:  It is estimated that the study be fully completed by January 2024.

HIPAA COMPLIANT FORM

Title: A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)

Associated condition: Colorectal Cancer/ Colonoscopy

Status: Currently enrolling

Brief summary: The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer.

Primary objectives: 

  1. Sensitivity of colorectal cancer detection
  2. Specificity of advanced neoplasia detection

Estimated length of study:  It is estimated that the study be fully completed by January 2024.